Supplementation with α-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of β-oxidation in Zucker fatty rats

Murase, Takatoshi; Aoki, Masafumi; Tokimitsu, Ichiro

doi:10.1016/j.bbalip.2004.12.015

Cited by 62 publications

(51 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, ALA-DAG consumption could be useful for controlling body weight by maintaining or improving fat and energy metabolism. This underlying mechanism is supported by reports showing enhanced expression of β-oxidation related enzymes and genes in the small intestine 12 and in the liver 13 in rodents. Based on these reports, ALA-DAG is expected to enhance oxidation of diet-derived fat as well as body fat.…”

Section: Introductionsupporting

confidence: 70%

“…1 were both observed in this present study. Repeated consumption of ALA-DAG enhances β-oxidation in the small intestine 12 and liver 13 in rodents. Although the precise mechanism by which ALA-DAG consumption stimulates gene expression is not clear, it may be related to the metabolic pathway of ALA-DAG.…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, to gain further insight into the mechanism underlying the anti-visceral obesity effect of ALA-DAG, the recovery rate of 13 C-labelled dietary fat to 13 CO 2 in the breath was assessed as an indicator of dietary fat oxidation during either ALA-DAG or TAG treatment. The ALA-DAG treatment enhanced dietary fat utilization as energy compared to the TAG treatment in humans.…”

Section: Discussionmentioning

confidence: 99%

“…The assessment of dietary fat oxidation was performed as reported previously 16 18 . Briefly, before and after ingestion of the test meal 555 kcal, protein: fat: carbohydrate 17:30:52 as energy value containing 13 C-labelled triolein 400 mg , we collected breath samples in aluminum bags GL Science Inc., Tokyo, Japan every hour for 6 h. As the primary outcome, oxidation of dietary fat was assessed by measuring recovery rate of ingested 13 C-labelled triolein to 13 CO 2 in the breath. Recovery rate of 13 C was assessed by the combined use of an indirect calorimeter Arco Systems Inc., Chiba, Japan and an stable isotope ratio mass spectrometer ANCA-GSL; Sercon, Crewe, UK .…”

Section: Dietary Fat Oxidation Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Alpha Linolenic Acid-enriched Diacylglycerol Consumption Enhances Dietary Fat Oxidation in Healthy Subjects: A Randomized Double-blind Controlled Trial

et al. 2017

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Dietary Fat Oxidation Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

Alpha Linolenic Acid-enriched Diacylglycerol Consumption Enhances Dietary Fat Oxidation in Healthy Subjects: A Randomized Double-blind Controlled Trial

et al. 2017

View full text Add to dashboard Cite

“…Triglyceride levels in tissue or adipocytes were also measured with commercial kits (Wako Pure Chemical Industries) after lipid extraction. ␤-Oxidation was measured as described previously (14). The activity was determined by counting the radioactivity and expressed as relative activity compared with untreated db/db mice.…”

mentioning

confidence: 99%

Therapeutic Potential of Peroxisome Proliferators–Activated Receptor-α/γ Dual Agonist With Alleviation of Endoplasmic Reticulum Stress for the Treatment of Diabetes

et al. 2008

View full text Add to dashboard Cite

OBJECTIVE-Peroxisome proliferator-activated receptor (PPAR)␣/␥ dual agonists have the potential to be used as therapeutic agents for the treatment of type 2 diabetes. This study evaluated the function of macelignan, a natural compound isolated from Myristica fragrans, as a dual agonist for PPAR␣/␥ and investigated its antidiabetes effects in animal models.RESEARCH DESIGN AND METHODS-GAL4/PPAR chimera transactivation was performed and the expression of PPAR␣/␥ target genes was monitored to examine the ability of macelignan to activate PPAR␣/␥. Additionally, macelignan was administrated to obese diabetic (db/db) mice to investigate antidiabetes effects and elucidate its molecular mechanisms.RESULTS-Macelignan reduced serum glucose, insulin, triglycerides, free fatty acid levels, and triglycerides levels in the skeletal muscle and liver of db/db mice. Furthermore, macelignan significantly improved glucose and insulin tolerance in these mice, and without altering food intake, their body weights were slightly reduced while weights of troglitazone-treated mice increased. Macelignan increased adiponectin expression in adipose tissue and serum, whereas the expression and serum levels of tumor necrosis factor-␣ and interleukin-6 decreased. Macelignan downregulated inflammatory gene expression in the liver and increased AMP-activated protein kinase activation in the skeletal muscle of db/db mice. Strikingly, macelignan reduced endoplasmic reticulum (ER) stress and c-Jun NH 2 -terminal kinase activation in the liver and adipose tissue of db/db mice and subsequently increased insulin signaling. T he worldwide prevalence of type 2 diabetes is steadily rising; therefore, in addition to a more aggressive approach in managing diabetes through diet and exercise, antidiabetes agents that ameliorate insulin resistance and hyperlipidemia are also needed. CONCLUSIONS-MacelignanAs members of the nuclear hormone receptor superfamily, peroxisome proliferator-activated receptors (PPARs) bind to specific DNA response elements as heterodimers with the retinoid-X receptor to control glucose and lipid metabolism, which offers a promising therapeutic approach for treating the metabolic syndrome (1). There are several PPAR isoforms, including PPAR ␣, ␥, and ␦ that share 60 -80% homology in the ligand-and DNA-binding domains (2). Widely expressed in the liver, PPAR␣ functions in the catabolism of fatty acids responsible for decreasing serum triglyceride levels and increasing HDL cholesterol levels in dyslipidemia (3). Therefore, PPAR␣ agonists have the potential to be used to ameliorate insulin resistance and hyperlipidemia. Moreover, PPAR␥ is highly expressed in adipocytes and is involved in adipocyte differentiation, lipid storage, glucose homeostasis, and adipocytokine regulation, which can improve insulin sensitivity and glucose tolerance (4). The primary issue with the utility of classic full PPAR␥ agonists is that they exert a variety of side effects, chiefly weight gain due to edema and increased fat mass (5). However, the side effects ...

show abstract

Diacylglycerols

Wang¹,

Lai²,

Lee³

et al. 2020

Bailey's Industrial Oil and Fat Products

View full text Add to dashboard Cite

Diacylglycerols (DAGs) are natural components of various edible oils. Typically, the level of DAGs in edible oils is below 5% of total oil; however, several edible oils have levels above 5%. Also, DAGs have been used as emulsifiers for use in food systems, particularly baked goods, and are approved as such. Human consumption of DAG has been estimated as 3 g per day.The following article focuses on experimental data supporting different metabolic characteristics of 1,3‐DAG or DAG oil containing 1,3‐DAG, synthesis of DAGs, applications of DAG in food industries, and patents. Relevant areas of observed differences between 1,3‐DAG/DAG oil and TAG/TAG oil metabolism include postprandial lipid metabolism and use of macronutrient fuels. Observations from animal and human experimental data are included.

show abstract

Supplementation with α-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of β-oxidation in Zucker fatty rats

Cited by 62 publications

References 37 publications

Alpha Linolenic Acid-enriched Diacylglycerol Consumption Enhances Dietary Fat Oxidation in Healthy Subjects: A Randomized Double-blind Controlled Trial

Alpha Linolenic Acid-enriched Diacylglycerol Consumption Enhances Dietary Fat Oxidation in Healthy Subjects: A Randomized Double-blind Controlled Trial

Therapeutic Potential of Peroxisome Proliferators–Activated Receptor-α/γ Dual Agonist With Alleviation of Endoplasmic Reticulum Stress for the Treatment of Diabetes

Diacylglycerols

Contact Info

Product

Resources

About